Revenue $6.59B, up 9.4% on a year earlier. MedSurg net sales $3.62B, down 3.9%. Orthopaedics net sales $2.96B, up 31.5%. Diluted EPS $3.30 against $2.29.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $6.59B | $6.02B | $6.02B | +9.4% |
| Operating income | $1.66B | $936.00M | $1.11B | +49.1% |
| Net income | $1.28B | $745.00M | $884.00M | +44.3% |
| Diluted EPS | $3.30 | $1.93 | $2.29 | |
| Operating cash flow | $1.26B | $581.00M | $1.11B | +13.5% |
| Capital expenditures | -$202.00M | -$166.00M | -$183.00M | |
| Free cash flow | $1.06B | $415.00M | $928.00M | +14.1% |
| Dividend per share | $0.88 | $0.88 | $0.84 |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| MedSurg net sales | $3.62B | $3.77B | -3.9% |
| Orthopaedics net sales | $2.96B | $2.25B | +31.5% |
| Reported net sales growth | 9.4% | 11.07% | |
| Constant Currency Net Sales Growth | 9% | 10.3% | |
| Hips net sales | $479.00M | $466.00M | +2.8% |
| Knees net sales | $693.00M | $640.00M | +8.3% |
| Organic net sales growth | 9% | 10.2% | |
| MedSurg and Neurotechnology organic net sales growth | 9.2% | 11% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Stryker (SYK) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/SYK/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
